Plagiarist Professor Junghun Suh at Seoul National University

The following emails, to which Junghun Suh did not responded, contain both confirmation, that especially Alzheimer's disease and prion diseases can be combated causally and these emails contain evidence of plagiarism of Junghun Suh at Seoul National University:

Dear Professor Dr. Suh,

when would you respond to my previous email?

If you do not respond within 5 days, I will publish my evidence of your plagiarism at first as a blog.

Sincerely,

Alexander Cherkasky

Dear Professor Dr. Suh,

my name is Alexander Cherkasky, I am award-winning and media-highlighted inventor and biologist, and I have found your articles and patent documents about artificial proteolytic substances. I have my published patent document DE19953696 „Selective Proteolytic Synzymes“ (filed on November 9, 1999 and published on May 10, 2001) and my claim 2 is the following:

„Selective proteolytic synzymes (SPS), wherein a proteolytic enzyme analogue (synzyme) will be coupled with a specific beta-amyloid-binding molecule, prion-binding molecule, or huntingtin-binding molecule or other molecule; through the resulting molecule it is possible to cleave a plaque or pathogenic (poly)peptide specifically, selectively.“

Only this claim covers every selective, target-specific proteolytic artifical enzyme, i.e. catalyst. Thus only because of this my claim and the fact, that you have not referenced this my patent document claiming priority and damaging novelty worldwide, your publications (both in scientific and patent literature) since 1999, (for example "Synthetic Artifical Peptidases and Nucleases Using Macromolecular Catalytic Systems", Accounts of Chemical Research/Vol.36, NO.7, 2003, pages 562-570, (for example the statement in the abstract: „A small artificial protease selective for a macromolecular target protein was synthesized. Target-specific artifical proteases can be used as protein-cleaving catalytic drugs“) and „Progress in Designing Artifical Proteases: A New Therapeutic Option for Amyloid Diseases“, Asian Journal of Organic Chemistry, 2014, 3, pages 18-32, (for example the statement in the abstract: „Application of the target-selective artifical proteases led to a therapeutic option for amyloid diseases, such as Alzheimer's disease and diabetes“)) can be considered as not novel and not inventive.

Thus I ask you to give a statement about this my evidence.

On my person:

I was born 1981 in Zaporozhye, Ukraine, living since 1996 in Dusseldorf, Germany, have finished Goethe-Gymnasium and Heinrich-Heine-University in Dusseldorf, my inventions include causal therapeutic solutions for combating cancer, viruses (both in and outside of cells), autoimmune and immune complex diseases, inventions for rejuvenation and tissue regeneration, inventions of novel multi-parallel diagnostic and gene sequencing systems, new materials and high-quality synthetic diamonds, and I have German patents and published American, international and German patent applications claiming priority and novelty worldwide.

Known media including Stern wrote about me and I got bronze medal “For Outstanding Achievements” and the Honorary Certificate at the (largest in Germany) inventors competition IENA (Ideas-Inventions-New Products) 2003 in Nuremberg. In addition, I offer innovative solving of scientific and technological problems in biomedicine, biotechnology and material science, and for creating and improvement of intellectual property in these fields.

My patent documents were referenced in more than 25 patents of companies, universities and research institutes in 10 countries, in The USA, Canada, Spain, France, UK, Japan, China, Switzerland, Belgium and Germany.

The following is the list of these references:

1) My published patent document WO2006/136892 was referenced in the patent documents EP2447277 and WO2012055985 (for anti-HIV vaccines) of the Spanish company Laboratorios del Dr. Esteve and the research organization Fundacio Privada Institut de Reserca de la SIDA-Caixa

2) My patent DE19937512 was mentioned in the US Patent US7163658 (for sequencing of nucleic acid sequences) of the American inventor Rouvain Bension

3) DE19937512 mentioned in the US Patent US8153438 of Halcyon Molecular

4) DE19953696 mentioned in the US Patent US7557182 of the Canadian firm Angiochem

5) DE19953696 mentioned in the US Patent US7902156 of Angiochem

6) DE19953696 mentioned in the US Patent US8710013 of Angiochem

7) DE19953696 mentioned in the US Patent US8828925 of Angiochem

8) DE19953696 mentioned in the US Patent US8828949 of Angiochem

9) DE19953696 mentioned in the US Patent US8853353 of Angiochem

10) DE19953696 mentioned in the US Patent US8921314 of Angiochem

11) DE19953696 mentioned in the US Patent US8969310 of Angiochem

12) DE19953696 mentioned in the US Patent US9161988 of Angiochem

13) DE19953696 mentioned in the US Patent US9173891 of Angiochem

14) DE19953696 mentioned in the US Patent US9365634 of Angiochem

15) DE19953696 mentioned in the US Patent US9221867 of Angiochem

16) DE19822406 mentioned in the US Patent US8034766 of the American company E I du Pont de Nemours and Company and University College London

17) DE19822406 mentioned in the US Patent US8431526 of E I du Pont de Nemours and Company

18) DE19925052 mentioned in the US Patent US7999073 of the Swiss company Lonza

19) DE19925052 mentioned in the US Patent US7320859 of the German firm Amaxa sold to Lonza

20) DE19925052 mentioned in the US Patent US9260471 of the American company Sirna Therapeutics

21) DE19925052 mentioned in the US Patent US9181551 of Sirna Therapeutics

22) US20080242565 mentioned in the US Patent US8273694 von Americans Jeffrey Brown, Joseph Duimstra and Jason Wells

23) DE10160248 (especially for the Fc-AChR fusion proteins against the autoimmune disease Myasthenia gravis) was mentioned in the US Patent US9243071 of the Japanese company Nihon Pharmaceutical (Tokyo, JP)

24) DE10162870 mentioned in the US Patent US8679500 of the Institute National de la Sante et de la Recherche Medicale (INSERM) (Paris, FR), Universite de Bretagne Occidentale (Brest, FR) and Centre National de la Recherche Scientifique (CNRS) (Paris, FR)

25) DE10162867 mentioned in the US Patent US8772254 of Devgen N.V. in Belgium

26) DE102007027596 mentioned in the Chinese Patent CN102718882 of the University Nanjing Agricultural

The search can be made for example in the patent literature data bank of the United States Patent and Trademark Office http://patft.uspto.gov/ and in Google Patents.

I will be glad to get your soon response.

Sincerely,

Alexander Cherkasky

Dipl.-Biol. (M.Sc.) Alexander Cherkasky

Prinz-Georg-Str. 5

40477 Duesseldorf

Germany

Tel: +49 211 482179

Email: alexcherkasky@googlemail.com